Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DHP-300
- Development stage
- Unknown
- Lead developer
- Dhp Korea
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Small Molecules, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
DHP-300 (also known as AT02) is a fixed-dose combination ophthalmic solution developed by Dhp Korea Co., Ltd. for the treatment of dry eye syndrome. It consists of sodium hyaluronate (0.3%) and carboxymethylcellulose sodium (0.5%). Sodium hyaluronate is a naturally occurring glycosaminoglycan that provides lubrication and promotes corneal epithelial repair by binding to the CD44 receptor. Carboxymethylcellulose sodium is a mucoadhesive polymer that increases the viscosity of the tear film and prolongs its retention on the ocular surface. Together, these components work synergistically to stabilize the tear film, reduce ocular surface friction, and alleviate symptoms of dryness and irritation. The formulation was evaluated in a Phase II clinical trial (NCT02643303) alongside other concentrations (DHP-101 and DHP-500) to determine optimal efficacy and safety in patients with dry eye syndrome.
- Brand names
- DHP-300DHP300DHP 300
- Other names
- sodium hyaluronate + carboxymethylcellulose sodium
02
Targets
CD44 (CD44 antigen)
Beyond the preview
Go deeper on DHP-300.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DHP-300.